Acta clinica Croatica, Vol. 59. No. 4., 2020.
Original scientific paper
https://doi.org/10.20471/acc.2020.59.04.01
Combined Treatment with Bevacizumab and Triamcinolone Acetonide for Macular Edema Due to Retinal Vein Occlusion
Maja Vinković
; Josip Juraj Strossmayer University of Osijek, Faculty of Medicine, Osijek, Croatia; Department of Ophthalmology, Osijek University Hospital Centre, Osijek, Croatia
Damir Bosnar
; Josip Juraj Strossmayer University of Osijek, Faculty of Medicine, Osijek, Croatia; Department of Ophthalmology, Sveti Duh University Hospital, Zagreb
Eugenia Tedeschi Reiner
; Josip Juraj Strossmayer University of Osijek, Faculty of Medicine, Osijek, Croatia; Department of Ophthalmology, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia
Gabriella De Salvo
; Department of Ophthalmology, Southampton University Hospital, Southampton, United Kingdom
Suzana Matić
; Josip Juraj Strossmayer University of Osijek, Faculty of Medicine, Osijek, Croatia; Department of Ophthalmology, Osijek University Hospital Centre, Osijek, Croatia
Abstract
The purpose of this study was to determine the efficacy of combined intravitreal
bevacizumab and triamcinolone in the treatment of macular edema due to retinal vein occlusion. A
prospective randomized trial was conducted in the Department of Ophthalmology, Osijek University
Hospital Centre in Osijek including 51 patients divided into three groups depending on the drug
received. The first group received 1.25 mg intravitreal bevacizumab, the second group received 1 mg
intravitreal triamcinolone, and the third group received a combination of 1.25 mg bevacizumab and 1
mg intravitreal triamcinolone on the same day. Changes in the central macular thickness, intraocular
pressure and visual acuity were monitored during the follow up period. The retinal perfusion status was
evaluated by fluorescein angiography. The group that received combined treatment had better outcome
in terms of reduction of macular thickness. There was no statistically significant intraocular pressure
elevation among the three treatment groups or within each group of patients. A positive trend regarding
visual improvement was observed in the group receiving combined treatment in spite of the lowest
initial visual acuity, highest value of macular thickness and longest mean duration of symptoms. In
conclusion, combined treatment with bevacizumab and triamcinolone for the treatment of retinal vein
occlusion is more potent, safe, efficient and cost-effective. It can also be recommended because fewer
injections are needed in patients undergoing treatment for macular edema.
Keywords
Retinal vein occlusion; Macular edema; Intravitreal application; Triamcinolone; Bevacizumab
Hrčak ID:
253466
URI
Publication date:
1.12.2020.
Visits: 1.829 *